

CorNotes

CVI SEMINAR SERIES

There will be no CVI Seminars during the month of August. CVI Seminars resume in September. If you are interested in sponsoring a visiting professor, please contact Dr. Leanne Cribbs at x72817.

CVI JOURNAL CLUB

August 14.....Dr. K. Byron
August 28.....Dr. L. Cribbs

CVI Journal Club is held at 12:00 noon in the CVI Research Division Conference Room, Rm 5215. For further information, contact Dr. Ken Byron at x72819.

RECENT PUBLICATIONS FROM THE CVI

Henze M, Hart DL, Samarel AM, Barakat JA, Eckert L, Scrogin KE. Persistent alterations in heart rate variability, baroreflex sensitivity and anxiety-like behaviors during development of heart failure in the rat. *Am. J. Physiol. Heart Circ. Physiol.*, 295:H29-38, 2008 (*with accompanying Editorial Focus by M Pagani and D Lucini*).

Havasi A, Li Z, Wang Z, Martin JL, Botla V, Ruchalski K, Schwartz JH, Borkan SC. Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism. *J Biol Chem.* 283(18):12305-12313, 2008.

Bossuyt J, Helmstadter K, Wu X, Clements-Jewery H, Haworth RS, Avkiran M, Martin JL, Pogwizd SM, Bers DM. Ca^{2+} /calmodulin-dependent protein kinase II delta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. *Circ Res.* 102(6):695-702, 2008.

Chung J, Nguyen AK, Henstridge DC, Holmes AG, Chan MH, Mesa JL, Lancaster GI, Southgate RJ, Bruce CR, Duffy SJ, Horvath I, Mestrlil R, Watt MJ, Hooper PL, Kingwell BA, Vigh L, Hevener A, Febbraio MA. HSP72 protects against obesity-induced insulin resistance. *Proc Natl Acad Sci U S A.* 105(5):1739-1744, 2008.

Walenga JM, Drenth AF, Mayuga M, Hoppensteadt DA, Prechel M, Harder S, Watanabe H, Osakabe M, Breddin HK. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. *Clin Appl Thromb Hemost.* 14(3):325-331, 2008.

Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. *Semin Thromb Hemost.* 34(1):86-96, 2008.

Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. *Semin Thromb Hemost.* 34(1):74-85, 2008.

Walenga JM, Bick RL, Messmore HL. Antigenic (immunogenic) profiling of bovine thrombin and its purified forms. *Clin Appl Thromb Hemost.* 14(2):133-134, 2008.

Hoppensteadt DA, Walenga JM. The relationship between the antiphospholipid syndrome and heparin-induced thrombo-cytopenia. *Hematol Oncol Clin North Am.* 22(1):1-18, 2008.

Untch BR, Jeske WP, Schwartz J, Botkin S, Prechel M, Walenga JM, Bakhos M. Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. *Clin Appl Thromb Hemost.* 14(2):141-148, 2008.

WHITE MEMORIAL FUND

Just another reminder that an endowment fund has been established to defray the cost of student travel and presentation at scientific meetings, and to support the cost of publishing scientific manuscripts by medical and graduate students working in cardiovascular research. The endowment has been funded by Richard E. White and Angeline (Faye) Schrater in memory of Mr. White's parents. Faculty members who require travel support for their students to attend scientific meetings, or to defray publication costs of student papers, should direct written requests for funding to Dr. Samarel, Director of Research, CVI.